Minireview
British Journal of Cancer (2009) 100, 1–7. doi:10.1038/sj.bjc.6604767 www.bjcancer.com
Published online 11 November 2008
Antiangiogenic drugs in ovarian cancer
G C Kumaran1, G C Jayson1 and A R Clamp1
1Department of Medical Oncology, Cancer Research UK and University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK
Correspondence: Dr G Kumaran, Translational Angiogenesis Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK. E-mail: gkumaran@picr.man.ac.uk
Received 19 December 2007; Revised 8 October 2008; Accepted 13 October 2008; Published online 11 November 2008.
Abstract
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
Keywords:
angiogenesis, vascular endothelial growth factor, angiogenesis inhibitors, ovarian neoplasms, biomarkers, adverse effects
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Targeted therapies Goldie?Coldman and bevacizumab beyond disease progression
Nature Reviews Clinical Oncology News and Views (01 Jun 2009)
